Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,999.00
Bid: 1,997.00
Ask: 1,998.00
Change: 34.00 (1.73%)
Spread: 1.00 (0.05%)
Open: 1,991.00
High: 2,028.00
Low: 1,983.00
Prev. Close: 1,965.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Construction, pharma, gold miners seen as Europe's top Trump trades

Wed, 09th Nov 2016 14:03

(Adds extra companies)

LONDON, Nov 9 (Reuters) - Global markets reacted onWednesday with concern to Donald Trump's surprise victory in theU.S. presidential election, but construction, pharma and goldmining stocks emerged as big winners in the European tradingsession.

Gains in those three sectors helped pull European stocks off their early lows that had followed a slump in WallStreet futures. The European index had been expected to open asmuch as 4 percent lower on the election outcome but in the endwas only down about two percent at the outset.

At 1358 GMT the index was down 0.4 percent.

Healthcare stocks were the biggest outperformers, up2.8 percent, followed by basic resources, up 2.4percent, and construction and materials, up 1.2 percent.

The STOXX 600 was down 0.6 percent by midday trading.

Markets had expected Democrat contender Hillary Clinton towin the election rather than Trump, a political outsider with noexperience of public office. Growth-sensitive shares such asautos, financial and travel shares all came under pressure fromthe uncertainty over what a Trump presidency will look like.

Stocks with substantial revenue exposure to the Mexicanpeso, and some with U.S. exposure, were also hit as bothcurrencies have come under pressure.

However, stocks of companies with American exposure thatstand to benefit from Trump's spending plans are seeing a lift.And those that have costs in pesos, rather than derive revenuesfrom Mexico, are also "winners" from the election result.

TRUMP WINNERS

* FRESNILLO - Gold miners are safe-haven playswhich benefit in times of uncertainty. Fresnillo is in additiona Mexico-based, London-listed, dollar-earning company. As suchthe 13 percent slide in the peso provided another lift toFresnillo. Its shares were up 9 percent on Wednesday, the topSTOXX 600 gainer.

* BAE SYSTEMS - Trump's non-committal stance onsupporting NATO allies might prompt increased defence spendingin Europe. Societe Generale picked out BAE Systems as a stockthat could benefit, and say that the sector is at a 5 percentdiscount to the European market and a 20 percent discount to theU.S. defence sector. The stock rose over 3 percent to anall-time high.

* HIKMA, BB BIOTECH - Pharmaceuticals hadbeen inversely correlated with the chances of a Clintonpresidency, as she has proposed higher regulation of pricing inthe sector. Hikma and BB Biotech were both up over 7 percentafter Trump won. Barclays had picked out Hikma as a beneficiaryif Trump won ahead of the election, deriving around half of itsrevenues from the United States. Shire and Novo Nordisk also rallied strongly.

* CRH - The construction firm hit a nine-year highon Wednesday as Trump has pledged to boost infrastructurespending. Trump's acceptance speech, which struck a conciliatorynote and avoided reference to controversial policies mentionedon the campaign trail, reiterated his commitment to increasedinfrastructure spending. CRH derives 50 percent of its revenuesfrom the United States.

* ASHTEAD - Ashtead is identified by Deutsche Bankas the European firm with the highest exposure to increasedinfrastructure spending in the United States, with 84 percent ofits revenues derived there.

* HEIDELBERGCEMENT - Heidelbergcement has said itsees benefits in the medium term from a Trump presidency, eventhough investment might be delayed in the short run. It isexpected to benefit from increased infrastructure spending, andwas up 2.4 percent.

TRUMP LOSERS

* BBVA - BBVA is identified by Credit Suisse andSociete Generale as the European bank most exposed to Mexico,from where it derives around 30 percent of its revenues. Thestock would suffer if Trump got into power and scrapped theNorth American Free Trade Agreement, as he has pledged to do.BBVA was down 8.8 percent, its biggest one-day fall since theBrexit vote.

* TATE AND LYLE - Tate & Lyle fell 9 percent, andhas 10 percent exposure to the peso. BNP Paribas downgraded thestock to "underperform" on Wednesday, saying that its Mexicanexposure would weigh on sentiment and profits.

* VESTAS WIND - Renewable energy firms took apounding on concern that President-Elect Trump will cut supportto the sector as he looks to promote coal and other fossilfuels. Vestas derives 40 percent of its revenue from the UnitedStates, per Barclays, and was down 7.2 percent.

* NESTE - Concerns over Trump's approach to theenergy sector also hit Neste. The Finnish renewable diesel makerfell 6.2 percent as the dollar weakened, with concern mountingthat Trump would tweak a tax break for biofuels.

* HEINEKEN, AB INBEV - Brewers Heinekenand AB InBev have substantial exposure to emerging markets likeMexico. Even though food and beverage stocks are seen broadly asdefensive, these two stocks were down over 4 percent.

* DSV - Cantor Fitzgerald highlight transport andlogistics stocks as being at risk should a Trump presidencyresult in a slowdown in global trade. "The risk for the largerglobal freight forwarding operators... is that trade is impededwith new barriers, particularly with China." Denmark's DSV wasdown 3 percent. (Reporting by Alistair Smout; Editing by Gareth Jones)

More News
24 Feb 2022 10:31

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Read more
24 Feb 2022 07:58

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

Read more
24 Feb 2022 07:50

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

Read more
17 Feb 2022 16:08

UK earnings, trading statements calendar - next 7 days

Friday 18 February  
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 21 February 
Bank of Cyprus Holdings PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Tristel PLCTrading Statement
Wilmington PLCHalf Year Results
Tuesday 22 February 
Antofagasta PLCFull Year Results
Bank of Georgia Group PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Blancco Technology Group PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Coca-Cola HBC AGFull Year Results
Hargreaves Lansdown PLCHalf Year Results
HSBC Holdings PLCFull Year Results (at 0400 GMT)
InterContinental Hotels Group PLCFull Year Results
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Synectics PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wednesday 23 February 
Aston Martin Lagonda Global Holdings PLCFull Year Results
Barclays PLCFull Year Results
Capital & Counties Properties PLCFull Year Results
CAP-XX LtdHalf Year Results
Georgia Capital PLCFull Year Results
International Personal Finance PLCFull Year Results
Irish Residential Properties REIT PLCFull Year Results
Metro Bank PLCFull Year Results
Hochschild Mining PLCFull Year Results
Photo-Me International PLCFull Year Results
Rio Tinto PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCFull Year Results
Thursday 24 February 
Anglo American PLCFull Year Results
BAE Systems PLCFull Year Results
Centrica PLCFull Year Results
Conduit Holdings LtdFull Year Results
Derwent London PLCFull Year Results
Drax Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Inchcape PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Rathbone Group PLCFull Year Results
Ricardo PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
St James's Place PLCFull Year Results
Tremor International LtdFull Year Results
WPP PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.